Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Osheroff

Showing results (61-70 of 107) with videos related to

Pageof 11
Sort By:
The Journal of Biological Chemistry|February 25, 1980
Electrostatic interactions in cytochrome c. The role of interactions between residues 13 and 90 and residues 79 and 47 in stabilizing the heme crevice structureN Osheroff, D Borden, W H Koppenol, et al.
The Journal of Biological Chemistry|September 1, 1995
A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitorsY Hsiung, S H Elsea, N Osheroff, et al.
The Journal of Biological Chemistry|September 25, 1978
Definitaion of cytochrome c binding domains by chemical modification. Reaction of carboxydinitrophenyl- and trinitrophenyl-cytochromes c with baker's yeast cytochrome c peroxidaseC H Kang, D L Brautigan, N Osheroff, et al.
The Journal of Biological Chemistry|January 27, 1995
A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticineS H Elsea, Y Hsiung, J L Nitiss, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 1, 1979
Definition of cytochrome c binding domains by chemical modification: kinetics of reaction with beef mitochondrial reductase and functional organization of the respiratory chainS H Speck, S Ferguson-Miller, N Osheroff, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classesN Osheroff, A H Corbett, S H Elsea, et al.
The Journal of Biological Chemistry|October 15, 1991
Inhibition of eukaryotic topoisomerase II by ultraviolet-induced cyclobutane pyrimidine dimersA H Corbett, E L Zechiedrich, R S Lloyd, et al.
Biochemistry|November 26, 1999
DNA abasic lesions in a different light: solution structure of an endogenous topoisomerase II poisonS D Cline, W R Jones, M P Stone, et al.
Annales D'Endocrinologie|August 29, 2000
Biochemical mechanism of apoptotic executionW C Earnshaw, K Samejima, F Durrieu, et al.
Nucleic Acids Research|February 19, 2005
Mms22p protects Saccharomyces cerevisiae from DNA damage induced by topoisomerase IIE L Baldwin, A C Berger, A H Corbett, et al.
Pageof 11

Showing results (61-70 of 107) with videos related to

Sort By:
Pageof 11
The Journal of Biological Chemistry|February 25, 1980
Electrostatic interactions in cytochrome c. The role of interactions between residues 13 and 90 and residues 79 and 47 in stabilizing the heme crevice structureN Osheroff, D Borden, W H Koppenol, et al.
The Journal of Biological Chemistry|September 1, 1995
A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitorsY Hsiung, S H Elsea, N Osheroff, et al.
The Journal of Biological Chemistry|September 25, 1978
Definitaion of cytochrome c binding domains by chemical modification. Reaction of carboxydinitrophenyl- and trinitrophenyl-cytochromes c with baker's yeast cytochrome c peroxidaseC H Kang, D L Brautigan, N Osheroff, et al.
The Journal of Biological Chemistry|January 27, 1995
A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticineS H Elsea, Y Hsiung, J L Nitiss, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 1, 1979
Definition of cytochrome c binding domains by chemical modification: kinetics of reaction with beef mitochondrial reductase and functional organization of the respiratory chainS H Speck, S Ferguson-Miller, N Osheroff, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classesN Osheroff, A H Corbett, S H Elsea, et al.
The Journal of Biological Chemistry|October 15, 1991
Inhibition of eukaryotic topoisomerase II by ultraviolet-induced cyclobutane pyrimidine dimersA H Corbett, E L Zechiedrich, R S Lloyd, et al.
Biochemistry|November 26, 1999
DNA abasic lesions in a different light: solution structure of an endogenous topoisomerase II poisonS D Cline, W R Jones, M P Stone, et al.
Annales D'Endocrinologie|August 29, 2000
Biochemical mechanism of apoptotic executionW C Earnshaw, K Samejima, F Durrieu, et al.
Nucleic Acids Research|February 19, 2005
Mms22p protects Saccharomyces cerevisiae from DNA damage induced by topoisomerase IIE L Baldwin, A C Berger, A H Corbett, et al.
Pageof 11